Adds glucagon receptor agonism to the dual-incretin approach. The glucagon arm is hypothesised to raise energy expenditure and drive hepatic fat mobilisation, complementing the appetite suppression of GLP-1 and the adipose effects of GIP. The therapeutic challenge is balancing glucagon's energy-expenditure benefit against its hyperglycaemic potential — the incretin arms are intended to offset it.
Phase 2 results reported weight reductions larger than those seen with approved incretin agents, generating substantial attention. Phase 3 programmes are ongoing. Efficacy and safety are not established; no regulatory body has reviewed a complete dossier.
Not approved anywhere. Investigational. Material sold online as “research retatrutide” is not the clinical trial product, has no verified identity or purity chain, and is not lawfully available for human use.
Human safety profile is incompletely characterised by definition — that is what Phase 3 exists to determine. Trial data report dose-dependent gastrointestinal effects and heart-rate increases. Unknowns are the point: this is an unapproved investigational molecule.
Forge Bioenergy does not publish dosing, reconstitution, or administration protocols for any peptide. See our editorial policy for why. If you are considering any substance on this page, that conversation belongs with a licensed physician.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.